Synovus Financial Corp raised its stake in Allergan PLC. (NYSE:AGN) by 5.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 24,903 shares of the company’s stock after buying an additional 1,343 shares during the quarter. Synovus Financial Corp’s holdings in Allergan PLC. were worth $6,053,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of AGN. Waldron LP purchased a new stake in Allergan PLC. in the 1st quarter valued at $348,000. First Trust Advisors LP grew its holdings in Allergan PLC. by 3,350.3% in the 1st quarter. First Trust Advisors LP now owns 61,899 shares of the company’s stock valued at $14,789,000 after buying an additional 60,105 shares in the last quarter. Summit Securities Group LLC purchased a new stake in Allergan PLC. in the 1st quarter valued at $2,074,000. American Century Companies Inc. grew its holdings in Allergan PLC. by 10.2% in the 1st quarter. American Century Companies Inc. now owns 1,408,274 shares of the company’s stock valued at $336,465,000 after buying an additional 130,162 shares in the last quarter. Finally, FTB Advisors Inc. grew its holdings in Allergan PLC. by 1.5% in the 1st quarter. FTB Advisors Inc. now owns 21,123 shares of the company’s stock valued at $5,047,000 after buying an additional 314 shares in the last quarter. Institutional investors own 82.02% of the company’s stock.

Several analysts have issued reports on AGN shares. ValuEngine cut Allergan PLC. from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Cowen and Company set a $400.00 target price on Allergan PLC. and gave the company a “buy” rating in a report on Thursday, June 8th. Mizuho dropped their target price on Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a report on Friday, June 9th. Royal Bank Of Canada set a $284.00 target price on Allergan PLC. and gave the company a “buy” rating in a report on Monday, June 12th. Finally, Cantor Fitzgerald started coverage on Allergan PLC. in a report on Friday, June 16th. They issued a “neutral” rating and a $231.00 target price for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $273.34.

Shares of Allergan PLC. (NYSE AGN) opened at 204.65 on Friday. The firm has a market cap of $68.42 billion, a price-to-earnings ratio of 6.24 and a beta of 1.18. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The stock’s 50 day moving average price is $229.79 and its 200 day moving average price is $236.07.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. During the same quarter in the previous year, the firm posted $3.35 earnings per share. The company’s revenue was up 8.8% compared to the same quarter last year. Equities research analysts predict that Allergan PLC. will post $16.26 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Friday, August 18th were paid a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 1.37%. The ex-dividend date was Wednesday, August 16th. Allergan PLC.’s dividend payout ratio (DPR) is 9.95%.

WARNING: This report was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/23/synovus-financial-corp-has-6-05-million-holdings-in-allergan-plc-agn.html.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.